Akari Therapeutics (AKTX) Stock Forecast, Price Target & Predictions
AKTX Stock Forecast
Akari Therapeutics stock forecast is as follows: an average price target of $12.00K (represents a 367998.16% upside from AKTX’s last price of $3.26) and
AKTX Price Target
Akari Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 05, 2022 | - | H.C. Wainwright | $12.00K | $4.31K | 178.45% | 367998.16% |
The latest Akari Therapeutics stock forecast, released on Dec 05, 2022 by H.C. Wainwright company, set a price target of $12.00K, which represents a 178.45% increase from the stock price at the time of the forecast ($4.31K), and a 367998.16% increase from AKTX last price ($3.26).
Akari Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.26 | $3.26 | $3.26 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Akari Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akari Therapeutics's last price of $3.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Akari Therapeutics Financial Forecast
Akari Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| # Analysts | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - |
Akari Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Akari Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EBITDA | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
undefined analysts predict AKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akari Therapeutics's previous annual EBITDA (undefined) of $NaN.
Akari Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| Net Income | - | - | - | - | - |
| Avg Forecast | $-9.42M | $-5.65M | $-9.42M | $-6.73M | $-5.40M |
| High Forecast | $-9.42M | $-5.65M | $-9.42M | $-6.73M | $-5.40M |
| Low Forecast | $-9.42M | $-5.65M | $-9.42M | $-6.73M | $-5.40M |
| Surprise % | - | - | - | - | - |
Akari Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akari Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| SG&A | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
Akari Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKTX last annual SG&A of $NaN (undefined).
Akari Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EPS | - | - | - | - | - |
| Avg Forecast | $-1.00 | $-0.60 | $-1.00 | $-1.00 | $-1.00 |
| High Forecast | $-1.00 | $-0.60 | $-1.00 | $-1.00 | $-1.00 |
| Low Forecast | $-1.00 | $-0.60 | $-1.00 | $-1.00 | $-1.00 |
| Surprise % | - | - | - | - | - |
According to undefined Wall Street analysts, Akari Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKTX previous annual EPS of $NaN (undefined).
Akari Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $3.26 | $12.00K | 367998.16% | - |
| PCSA | Processa Pharmaceuticals | $1.34 | $9.00 | 571.64% | Buy |
| CAPR | Capricor Therapeutics | $4.59 | $14.00 | 205.01% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| SLNO | Soleno Therapeutics | $52.84 | $72.25 | 36.73% | Buy |
| AXLA | Axcella Health | $4.58 | $6.00 | 31.00% | Buy |
AKTX Forecast FAQ
Will Akari Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AKTX stock, the company can go up by 367998.16% (from the last price of $3.26 to the average price target of $12K), up by 367998.16% based on the highest stock price target, and up by 367998.16% based on the lowest stock price target.
Can Akari Therapeutics stock reach $5?
AKTX's average twelve months analyst stock price target of $12K supports the claim that Akari Therapeutics can reach $5 in the near future.
What are Akari Therapeutics's analysts' financial forecasts?
Akari Therapeutics's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-5.395M (high $-5.395M, low $-5.395M), average SG&A $0 (high $0, low $0), and average EPS is $-1 (high $-1, low $-1). AKTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-31.214M (high $-31.214M, low $-31.214M), average SG&A $0 (high $0, low $0), and average EPS is $-3.6 (high $-3.6, low $-3.6).